Physician

Shailendra Lakhanpal, M.D.

According to 2025 Medicare claims, Shailendra Lakhanpal, M.D. (NPI: 1538192570) practices medical oncology in the Birmingham, AL market, with the plurality of this provider's patient population coming from St. Clair, AL. This provider's primary affiliated billing organization is BIRMINGHAM HEMATOLOGY ONCOLOGY ASSOC LLC (NPI: 1841216389; TIN: 522170293) and primary practice location at 35235-3411.

Lakhanpal's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 368 traditional Medicare patients, billed 152,810 HCPCS/CPT codes, and received $2,172,571 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 3,239 prescription claims across 432 beneficiaries totaling $7,034,045 in drug costs, led by Revlimid (Lenalidomide). 2018 DME data shows 41 claims. Open Payments data shows 136 records totaling $32,877. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $2,154,763 and ending at $2,172,571. Concurrently, Part D prescription costs have moved from a lower plateau to a higher plateau, from $1,256,305 to $7,034,045. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $16,347 to $1,701.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	528	285,011	$2,154,763
2016	545	251,462	$2,230,068
2017	454	221,532	$1,679,414
2018	443	145,221	$1,770,206
2019	432	177,631	$2,240,851
2020	412	186,946	$2,157,957
2021	443	158,452	$2,562,280
2022	364	129,017	$1,831,315
2023	350	152,301	$1,448,713
2024	368	152,810	$2,172,571

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	328	2,812	$1,256,305
2016	335	2,743	$2,214,814
2017	326	2,574	$1,999,905
2018	328	2,535	$2,550,243
2019	353	2,604	$3,901,331
2020	359	2,972	$4,976,458
2021	376	3,011	$5,220,495
2022	391	3,299	$6,306,785
2023	414	3,298	$6,571,762
2024	432	3,239	$7,034,045

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	33	308	$57,639
2016	13	171	$28,138
2017	16	96	$30,285
2018	15	41	$33,696
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	154	455	$87
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	93	134	$61
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	196	410	$11
36415	Insertion of needle into vein for collection of blood sample	226	733	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	247	947	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	75	1,848	$1,133,786
Calquence	Acalabrutinib Maleate	58	1,736	$796,349
Cabometyx	Cabozantinib S-Malate	27	810	$669,789
Brukinsa	Zanubrutinib	46	1,380	$648,489
Lenalidomide	Lenalidomide	60	1,421	$625,496

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	125	$2,754	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	11	$30,123	PFIZER INC.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Shailendra Lakhanpal, M.D.?

Tedicare shows public-source Medicare data for Shailendra Lakhanpal, M.D. (NPI 1538192570), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Shailendra Lakhanpal, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Shailendra Lakhanpal, M.D.?

Shailendra Lakhanpal, M.D. is linked to BIRMINGHAM HEMATOLOGY ONCOLOGY ASSOC LLC (billing NPI 1841216389) in the available physician profile data.

Does Shailendra Lakhanpal, M.D. have Open Payments data?

Shailendra Lakhanpal, M.D. has 136 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.